Feature
MOTS-c: Where the Evidence Ends
Studies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?
PR Newswire
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
Phase 1 trial reported confirmed RECIST responses in 12 of 16 evaluable, heavily pretreated patients.
Key takeaways
- Twelve of sixteen evaluable patients had confirmed RECIST responses.
- Many patients had PSA reductions of at least 50 percent.
- Most treatment-related adverse events were mild to moderate.
